Flow cytometry enables studies of a number of different aspects of platelet function in response to a variety of platelet agonists. This can be done using only a small volume of whole blood, and also in blood with low platelet counts. These properties, together with the increasing number of flow cytometers available in hospitals worldwide makes flow cytometry an interesting option for laboratories interested in studies of platelet function in different clinical settings. This review focuses on practical issues regarding the use of flow cytometry for platelet function testing. It provides an overview of available activation markers, platelet agonists and experimental setup issues. The review summarizes previous experience and factors important to consider in order to perform high quality platelet function testing by flow cytometry. It also discusses its current use, and possibilities and challenges for future use of flow cytometry in clinical settings.
INTRODUCTION
Mild bleeding disorders caused by inherited platelet dysfunction are a diagnostic challenge 1 . At the same time, inhibition of platelet activation is of paramount importance in cardiovascular diseases. In light of this, there are multiple clinical reasons to measure platelet function. The "gold standard" since the 1960's is light transmission aggregometry on citrated platelet-rich plasma (PRP), but this method is cumbersome and results vary with the platelet count 2 . In addition, it requires a relatively large volume of blood and only investigates one aspect of platelet function, the aggregation potential. Improved methods for investigation of different aspects of platelet function are therefore in demand.
In flow cytometry, single cells are passed through one or more laser beams, where the light scatter (indicating cell size and granularity) and signal intensity from different fluorescently labeled markers bound to the cell can be measured. This enables studies of a number of different aspects of platelet function in response to a variety of platelet agonists. The possibility to obtain results from thousands of individual platelets in just a few seconds, and from just a few microliters of blood is also attractive, especially for pediatric patients. Another major advantage is that platelet function can be investigated in blood from patients with thrombocytopenia, as the technique does not require a certain cell count to give reliable results. Due to the versatility of flow cytometers, these instruments are now available in many hospitals for other applications. Thus, flow cytometry may be an attractive option for many laboratories wanting to perform platelet function testing.
This review focuses on practical issues regarding the use of flow cytometry for platelet function testing. It discusses its possibilities and limitations and reflects on its current and potential future use in clinical practice.
METHODOLOGICAL ISSUES Preparation of platelets
Due to the size difference as compared to other blood cells, platelets are easily distinguishable in whole blood samples. This allows platelet analysis by flow cytometry in diluted whole blood.
Although it is possible to use PRP or platelet suspensions as well, the diluted whole blood method first described by Shattil and colleagues in 1987 3 offers several advantages, as it reduces the risk of pre-activation and loss of larger/denser platelet populations (during e.g. centrifugation to produce PRP) 4, 5 . For some assays, the presence of other blood cells is also needed, such as when plateletleukocyte aggregates are analyzed.
The most common choice for blood anticoagulation is still sodium citrate (3.2 or 3.8%), but the use of other anticoagulants are increasing, such as hirudin, D-Phenylalanyl-L-prolyl-L-arginine
Chloromethyl Ketone (PPACK) 6 , corn trypsin inhibitor (CTI) and other options that do not interfere with the calcium levels of the blood. Strong calcium chelators such as ethylenediaminetetraacetic acid (EDTA) should be avoided as it dissociates the fibrinogen receptor glycoprotein (GP)IIb/IIIa irreversibly and thereby prevents fibrinogen binding 7 (although this can also be used to create a negative control for this analysis 8 ). Something worth to keep in mind when comparing results from platelets in different anticoagulants is that platelet responses seem to be higher in platelets exposed to citrate anticoagulation, despite a large dilution of the anticoagulant in the reaction mixture where platelets are activated (see Fig. 1A -C). This is not unique for flow cytometry, it has previously been reported that the potency of different GPIIb/IIIa antagonists differed depending on the anticoagulant used in the assay 9, 10 . In addition, an enhanced thromboxane production in conditions with low extracellular calcium levels has been suggested to cause a second wave of aggregation in response to adenosine diphosphate (ADP) in citrated plasma, something that was not observed at physiological levels of calcium [11] [12] [13] . The problem with thrombin inhibitors such as hirudin and PPACK is that these make it impossible to use thrombin for platelet activation. If thrombin is used, citrate anticoagulation is the common choice. Addition of the fibrin polymerization inhibitor peptide glycyl-L-prolyl-L-arginyl-L-proline (GPRP) [14] [15] [16] [17] to the reaction mixture is necessary if whole blood or PRP is to be used together with thrombin. With GPRP it is possible to avoid fibrin network formation, which will otherwise trap the platelets and potentially clog the flow cytometer. . Thus, the evidence is inconclusive to the potential effects of heparin as anticoagulant. In Fig. 1A -C, platelet responses in heparin were mostly intermediate to those in citrate and hirudin. We thus suggest that if heparinized blood is the only available option, it can be used if proper controls showing no signs of pre-activation are included and these are presented together with the results. It should also be kept in mind that the potential heparin-induced effects discussed here are completely unrelated to the dramatic immunological reaction leading to platelet binding and clearance in patients with heparininduced thrombocytopenia (HIT).
For blood collection, the general recommendations are to use minimal stasis and a large needle (19-21 gauge) to ensure a smooth blood flow and to discard the first portion of blood (at least 2 ml) to avoid pre-activation of platelets and inclusion of vessel wall material 21, 22 . Systematic mixing (by 6-10 times full inversion) of the tube after the blood draw is important to allow rapid exposure to the anticoagulant. After that, vigorous shaking (e.g. pneumatic tube transport) or temperature shifts during transportation to the lab has to be avoided, as these procedures have been shown to cause platelet pre-activation 23, 24 . By including a sample checking for spontaneous platelet pre-activation in the flow cytometry panel, it will be possible to find and potentially discard data that are unreliable due to pre-analytical activation of the collected platelets (discussed further below). Blood samples should be kept at room temperature prior to analysis
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, and actions taken to prevent temperature fluctuations. Both refrigeration and storage at 37°C affect platelet function 25 and should therefore be avoided.
With regards to the time from blood collection until the start of platelet function testing, not much data is available. Most published flow cytometry protocols for research state that preparation for testing was started "immediately" after blood collection. However, this is naturally difficult to achieve in clinical settings, and in worst case, differences in time between sampling and preparation in the control group and the patient material could be a possible cause of observed differences.
Therefore, it is very important to standardize both blood sampling conditions and time to function testing, and to choose a time interval achievable for all samples. There are reports stating that the platelet responses during the first hour after blood collection in citrate tubes are actually lower, but to varying degrees, and that a higher and more stable response is achieved in samples 1-2 hours after blood collection 26 . For a clinical study, this time interval may be a more reasonable and achievable target window, but it should be validated for the specific protocol used in the study.
Sample preparation
To avoid platelet aggregation, it is necessary to dilute the blood prior to platelet activation, a dilution of 1:12-13 was used in the original whole blood protocol 3 . It is also important to avoid vigorous mixing (use only brief low speed vortex or finger tapping, with no mixing during activation). To check for potential platelet aggregation during the activation procedure, a simple way to get a crude estimate is to count the time it takes to achieve the selected number of platelets during acquisition in activated vs. buffer-treated samples 27 . , important e.g. for generation of procoagulant platelets 35, 36 . Fig. 1D -F shows that transformation of the fibrinogen receptor GPIIb/IIIa into its high affinity state was somewhat inhibited in the presence of extracellular calcium, perhaps related to the down regulation of GPIIb/IIIa in highly activated platelets 37 . On the other hand, both P-selectin and lysosomal-associated membrane protein-1 (LAMP-1) exposure was increased in the presence of calcium, showing that even though the intracellular calcium stores are sufficient to enable granule exocytosis 38 , this process is enhanced in the presence of extracellular calcium. In some cases, the addition of calcium is absolutely necessary, such as when using annexin V to detect the exposure of phosphatidylserine (PS) [39] [40] [41] , or when studying the assembly of coagulation factor complexes on the platelet surface 42 .
Identification of platelets
As compared to standard flow cytometry settings, such as those for leukocyte analysis, platelet protocols use logarithmic scaling for forward and side scatter detectors. In addition, the standard threshold in forward scatter applied for leukocytes needs to be significantly decreased, as platelet- Platelets can then be identified by fluorescence from the identification marker together with one of the scatter parameters, collecting data from at least 5,000-10,000 platelets. Subsequent gating to exclude non-single events is recommended as a next step. If these events are frequent and caused by co-incidence 44 , where multiple particles pass the laser together, further dilution may help.
One potentially interesting feature in the platelet activation response is the release of platelet microparticles upon activation. Many reports have been published where microparticles formed in vivo are detected, and recent reviews report findings in numerous pathological conditions 45, 46 . As this review focuses on platelet function testing, studies of microparticles alone will not be discussed.
However, for all types of studies on microparticles, it is important to note that the use of beads for size determination is not accurate, as the refractive indexes of polystyrene beads and cell fragments differ 47 . Due to antigen depletion on smaller sized particles, markers with low surface density may not be detectable on microparticles by flow cytometry 48 . There is also a lower limit for the size of particles possible to detect by flow cytometry, and many particles fall below this limit (the "iceberg theory") or will be counted together as one larger particle ("swarm detection") [49] [50] [51] . Thus, the majority of detected particles with standard protocols have been suggested to be "smaller platelets"
rather than microparticles 52 . However, the use of a fluorescence threshold on a highly expressed marker (e.g., GPIIb/IIIa) instead of a scatter threshold enables detection of smaller platelet-derived particles 53, 54 . It is also to be noted that separation of particles based on their size is better accomplished using forward scatter on some brands of flow cytometers, while others brands give better size separation using the side scatter parameter 55 .
Platelet activation markers
For diagnosis of patients with mild bleeding disorders, analysis of expression of platelet surface glycoproteins is essential. Recent guidelines suggest analysis of GPIIb (CD41, integrin αIIb), GPIIIa (CD61, integrin β3), GPIbα (CD42b), and GPIX (CD42a) as a first step and GPIa/IIa (α2β1), GPIV, and GPVI as a second step 56 . However, as this review focuses on tests of platelet function, receptor level tests will not be further discussed here. As the surface expression of many of these receptors change upon platelet activation 57 , these tests should not be performed on activated platelets. Table 1 summarizes different platelet activation events and markers used to detect these. Directly labeled antibodies towards many of these markers are now commercially available, enabling the setup of more advanced protocols including several markers in the same tube, which is advantageous to reduce the number of tubes if many platelet agonists are to be tested. To minimize problems due to spectral overlap, efforts to choose fluorophores with minimal spectral overlap, careful titration of antibodies and proper compensation (potentially using capture beads if the antigen expression is low even on strongly activated platelets) are important issues to consider in the protocol setup 32 .
Also note that compensation values obtained for platelets do not always match what is commonly
reported for larger cells. To determine the boundary between positive and negative platelets, both properly chosen isotype controls and fluorescence-minus-one (FMO) controls are useful 31, 32 . The gate is usually placed to get 1-2% positive platelets in the isotype sample 28 . In some cases, such as markers for activated GPIIb/IIIa and annexin V as marker for PS exposure, binding of the marker can be prevented by other means (EDTA treatment 8 or absence of calcium, respectively), making it possible to create a negative control without the use of isotype antibodies. and rosamine (e.g.
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Alternative ways to test platelet function by flow cytometry
Other options to study platelet activation using flow cytometry includes the agonist-induced formation of platelet microaggregates, detectable by residual platelet counting 101 , the adhesion of platelets to protein-coated polystyrene beads 102 , and the formation of platelet-leukocyte aggregates 103 in circulation or upon platelet activation [104] [105] [106] . In studies of platelet-leukocyte aggregate formation, co-incidence issues need to be taken into account 107 and distinguished from true aggregates. It also needs to be recognized that platelet-monocyte aggregates form spontaneously after blood collection (see Fig. 1K ), so to be useful in a clinical setting, samples need to be fixed immediately after collection 103 or even with fixation added to the blood collection tube 108 .
Measurements of circulating platelet aggregates or P-selectin-positive platelets have been reported in a number of clinical conditions. However, the rapid shedding of P-selectin on circulating platelets 109 and the potential risk of spontaneous formation after blood collection complicates the interpretation of the results. Protocols including immediate fixation have been described 110 , and might be a possible solution to this problem. However, activated platelets are supposed to be attached to the site of damage and not circulating. Thus, measurement of receptors being cleaved off from activated platelets, such as soluble P-selectin, sGPVI or sCD40 ligand, might be better alternatives in this context.
Platelet activation
Platelet activation can be induced by addition of one or more platelet agonists to the diluted blood samples. Agonists can be added in a first separate step or be a part of the antibody mixture in which the blood is diluted. If pre-incubation with antibodies or inhibitors is needed for optimal performance, agonists can also be added in a subsequent step. Platelet aggregate formation can be avoided by a high enough dilution, gentle mixing and incubation in static conditions. Table 2 summarizes platelet agonists and receptor activation pathways amenable to testing by flow cytometry. However, it should be kept in mind that release of granule contents is contributing to the activation response by the more potent agonists. ADP receptor inhibition (especially P2Y12) and presence of apyrase will therefore decrease platelet responses significantly (see Fig. 1G-I ). The formation of thromboxane A2 (TXA2) from arachidonic acid seems to be of less importance, as aspirin treatment is often reported not to affect flow cytometry results [111] [112] [113] . The reason for this is somewhat unclear, but the lower cell density and absence of shear might be potential explanations.
The temperature used during activation of platelets will affect the response. The activation step is traditionally performed at room temperature, where higher activation responses are actually seen. It has also been claimed that the PAC-1 antibody is not stable at 37°C
114 , but this is not supported by our data, where pre-incubation of the antibody at 37°C did not alter its performance if the experiment was performed at room temperature (see Fig. 1J ). Another reason for experiments at room temperature might be that the number of tubes needed for testing of different activation conditions may be cumbersome to handle at 37°C, but it is possible to use a water bath or similar to perform the activation at other temperatures. In the case of annexin V, the binding has been reported to be enhanced at room temperature 115 . The concentrations of agonists vary between studies, in part due to the choice of anticoagulant, platelet preparation method, etc., but also due to the specific purpose of the study. If the aim is to induce formation of PS-exposing procoagulant platelets, high doses of collagen-and thrombinreceptor activating substances in combination are the most effective stimuli 86 , and presence of calcium and autocrine stimulation by ADP 137 are important components.
Studies investigating normal ranges for platelet function in normal donors have shown that the variation is relatively high, especially at low and medium doses of agonists 26, 138, 139 , and with a considerable overlap in responses between individuals with and without reported bleeding problems. Still, recent large studies of patients with platelet function defects using aggregometry suggest that a streamlined protocol with single doses of a number of agonists is enough to identify most patients 140, 141 . A similar approach might be considered for flow cytometry studies, where a suggestion is to use a dose where the percentage of platelets exposing an activation marker such as P-selectin (for which a full response can be expected) levels out in normal donors 26 . On the other hand, if the aim is to identify individuals with hyper-reactive platelets, aggregation studies suggest that sub-maximal doses are more indicative 142 . Control samples, where platelets are only treated with buffer, should always be included in the protocol in order to visualize the degree of spontaneous platelet pre-activation. This is commonly done by measuring P-selectin exposure, as this is a sensitive marker for pre-activated platelets that is not reversible in vitro 57, 143 . The level of pre-activation should also be reported, and samples showing too high pre-activation levels should be interpreted with caution or if possible excluded from evaluation. Information on the appropriate level to use as a threshold for pre-activation is scarce. It further depends somewhat on the resolution of the flow cytometer used and of course on the aim of the study. Our experience is that an upper threshold of around 15% P-selectin positive platelets usually identifies samples with an acceptable level of pre-activation.
Stopping the reaction
The activation is ended after an exact time by addition of a larger volume of buffer to stop the reactions. Direct inhibitors to the platelet agonists used, such as hirudin or apyrase, or a fixative may be added to this stopping solution. In clinical settings, a light formaldehyde fixation (0.5-1%) is often used to prolong the sample stability before analysis 28 . However, many fluorophores will show lower intensity, and some antigens may be destroyed by fixation. It is therefore important to test and optimize the protocol before starting a study, and keep conditions constant throughout to allow interpretations and comparisons to be done. As fixation affects the platelet membrane properties, it is especially important to verify how fixation affects markers detecting membrane changes, such as PS exposure and formation of microparticles, where fixation may lead to changes wrongly interpreted as being part of the physiological response. In cases where fixation is deemed impossible, flow cytometry analysis needs to be performed as soon as possible, as dilution alone will only keep the samples stable for a shorter period. The maximum time allowed should be tested, applied consistently within the trial participant groups and reported together with the results.
Analysis
Results from the analysis can be expressed either as the percentage of cells being positive for the marker, or the median fluorescence intensity (MFI) of the total platelet population. The percentage of positive platelets has been suggested to be advantageous in situations where all cells do not become positive 28, 144 , and also due to its assumed transferability between instruments, but only if
proper controls are applied to set the boundary between negative and positive platelets, as discussed above. The other alternative is the MFI, which reports the median signal from bound antibody for the total platelet population. This approach will be advantageous in situations where most platelets express the antigen, but where the level of expression could vary between individuals 21 or treatments. The geometric mean is an alternative to the median. The mean should not be used as a few highly positive events are often detected, which tend to make the mean unreliable. However, the drawback with MFI in a large clinical study with an extended patient recruitment or follow up period is that the flow cytometer performance may shift with time. Thus, the instrument stability over time needs to be verified for the results to be comparable. Control beads of different kinds are provided by the manufacturers to verify linearity and detector/laser performance over time, and should always be used to monitor instrument performance. As the MFI scaling is arbitrary, it is necessary to run fluorescence calibration beads allowing responses to be reported as Molecules of Equivalent Soluble Fluorochrome (MESF) 145 , if results are to be compared between instruments and over time in e.g. multicenter trials.
For clinical studies aiming to identify and/or diagnose patients with platelet dysfunction, it is essential to establish appropriate reference intervals. The guidelines from the British Society of Haematology for investigation of heritable platelet function disorders recommend that local, normal cut-off values are established using non-parametric statistics, but recognizes that this is not commonly done
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. Indeed, the intra-and inter-individual variation and the presence of high and low responders among normal donors make this a challenging task. Also, samples from 120 individuals are recommended to create a reference interval using non-parametric methods 146 . However, other approaches such as bootstrap-based procedures 147 or the robust method described by Horn and Pesce 148 may enable calculation of reference intervals with a lower number of reference samples 146, 149 .
CURRENT USE OF FLOW CYTOMETRY FOR PLATELET FUNCTION TESTING IN CLINICAL SETTINGS

Diagnosis of mild bleeding disorders
A survey regarding the diagnosis of patients with mild bleeding disorders including 202 laboratories in 37 countries was recently reported by the International Society of Thrombosis and Haemostasis (ISTH) 150 . A flow cytometer was available in 57% of the laboratories. It was used as a first step test in 23% and as a second step test in approximately two thirds of the laboratories. The main use was to study expression levels of receptors know to be absent in rare inherited platelet disorders such as Glanzmann's thrombastenia and Bernard-Soulier syndrome. 78 of the laboratories used flow cytometry to study alpha granule release, measuring P-selectin exposure upon activation. In addition to that, activation of fibrinogen receptor GPIIb/IIIa was relatively common, but only using a few agonists, often ADP and PAR1-AP (TRAP-6), while other tests, such as dense granule release, procoagulant activity or lysosomal release was assessed by less than 30 of the laboratories. Light transmission aggregometry was available in 73% of the laboratories and used for first line testing in 59%. Notably, out of an estimated number of 14,000 patients investigated each year, no abnormality was found in 60% of the cases, and only 9% of the remaining received a definite molecular diagnosis.
This indicates that the current battery of tests may be insufficient to indicate where a potential defect is located.
Transfusion medicine
Flow cytometry has been commonly used in transfusion medicine to investigate the in vitro quality of platelets in platelet concentrates (PCs) during storage and to assess how different preparation and storage conditions affect platelet properties [151] [152] [153] [154] . However, most studies have not included any addition of platelet agonists, but studied changes in spontaneous expression of receptors such as of GPIb (CD42b) and P-selectin after agonist stimulation has been found to decrease during storage [157] [158] [159] [160] , as well as the PAC-1 expression 161 . Agonist-induced formation of microparticles and exposure of LAMP-1 was recently suggested as potential new markers to detect deteriorating platelet function during storage 54 . How these findings correlate to in vivo performance of transfused platelets is however still unknown. Only a few studies have investigated the correlation between expression of activation markers and in vivo viability and the correlations reported so far have been low and varying between studies [162] [163] [164] . Thus investigation of the platelet activation potential using flow cytometry could potentially contribute to better results in this regard.
Anti-platelet drug testing
One commercial flow cytometry-based test has been developed to measure the function of the platelet P2Y12 receptor, with the aim to study the effect of anti-platelet drugs targeting this receptor (e.g. clopidogrel, prasugrel, ticagrelor). In the vasodilator-stimulated phosphoprotein (VASP) assay, platelets are incubated with either prostaglandin E1 (PGE1) or ADP+PGE1, and the phosphorylation state of VASP is measured to determine the degree of active P2Y12 receptor. The test has been compared to other approaches to measure P2Y12 inhibition in clinical settings, but the frequency of "non-responders" identified has been shown to vary considerably depending on the assay performed 165 . In addition, the correlations between the assays have been low in several studies 166 .
As an alternative to the flow cytometry protocol, an ELISA method for VASP phosphorylation has been developed. This enables testing of plasma samples, thereby making remote testing easier to perform 167 . Direct or indirect methods to detect platelet GPIIb/IIIa antagonists, as well as methods based on arachidonic acid to detect aspirin use have been described, but none has gained widespread attention or commercial use. A recent study comparing flow cytometry to other methods to determine platelet function in patients on dual antiplatelet therapy report low correlations between the different arachidonic acid based methods 168 . The above mentioned potential issues with cell lysis by arachidonic acid could be one explanation, but that needs to be further investigated.
Thrombosis and disease risk assessment
The potential to form procoagulant platelets upon strong activation with thrombin in combination with convulxin or collagen has been measured in a number of disease states. Increased formation of procoagulant platelets (measured as coated platelets) has been reported in thrombotic conditions such as ischemic stroke and transient ischemic attack [169] [170] [171] [172] and lower formation in hemorrhagic conditions such as hemorrhagic stroke [173] [174] [175] . However, as these reports originate from a single center, additional studies from independent groups are needed to strengthen these findings.
Platelet function tested by flow cytometry was also recently reported to be associated with bleeding severity in children with immune thrombocytopenia (ITP) independent of the platelet count 176 .
Although not being platelet function tests, and with the limitations discussed previously, circulating P-selectin-positive platelets and platelet-leukocyte aggregates have been described in a number of conditions as reviewed by Linden et al 177 , with platelet-leukocyte aggregates being potentially more informative, as P-selectin is rapidly removed from the surface of activated platelets in vivo 109 . Table 3 , open up interesting future avenues. Especially in the field of mild bleeding disorders, it will be interesting to see if light transmission aggregometry in the future is challenged by flow cytometry for the diagnosis of these patients. Bleeding risk assessment in patients with thrombocytopenia is another interesting future possibility.
FLOW CYTOMETRY FOR PLATELET FUNCTION TESTING IN CLINICAL SETTINGS -NEW PERSPECTIVES
For assessment of thrombotic events, the situation is more complicated, as the mechanisms underlying these events are more complex. In case of persistent hypercoagulability or vessel wall problems, it is also important to keep in mind that all ex vivo platelet function studies only will target platelets that are still circulating. This means that a lower platelet activation response could be expected. Indeed, this was the case in a recent study by us, where lower platelet activation was found in circulating platelets in patients infected with hanta-virus with ongoing platelet destruction 180 . For anti-platelet drug testing or in acute settings, flow cytometry may be less useful, as the turn-around time might still be considered too long, despite the improvements regarding sample preparation mentioned above. Furthermore, the potential to use multi-color protocols also means that the data analysis and its interpretation will become increasingly complex. A future challenge may then be to develop and evaluate multi-parameter analysis algorithms with the potential to capture and identify defects and features of platelet functionality that may have diagnostic and/or prognostic potential. 
Advantages
Tests can be designed to include many different aspects of platelet function and surface expression in a single protocol.
Low volumes of blood are needed, which is advantageous in e.g. pediatric patients.
Whole blood can be used, thereby avoiding the risk of losing denser platelet populations or causing pre-activation by centrifugation steps.
Platelet function can be evaluated in thrombocytopenic patients.
Platelet pre-analytical activation can be easily tested and accounted for.
The field is still in its early days. Thus it seems possible that a well-designed and standardized protocol could be adopted by many researchers and diagnostic laboratories.
Limitations/challenges
Only cells in diluted suspensions can be used, so it is not possible to study aspects/signaling induced by platelet-platelet-contacts.
An increasing number of flow cytometers on the market increase the need for standardization efforts.
The preparation of samples is labor-intensive (but with potential improvements) and a skilled operator is needed to analyze the obtained results.
Many proposed protocols are not yet validated by studies of patients with well-defined defects.
End-point measurements are usually the only option.
Does not include any shear stress component.
CONCLUDING REMARKS
Flow cytometry allows a versatile and sensitive simultaneous testing of a multitude of platelet properties and functions. The high sensitivity requires knowledge of the level of platelet pre- 
